52,019 results match your criteria hypoglycemia


A case of hypercalcemia because of adrenal insufficiency induced by glucocorticoid withdrawal in a patient undergoing hemodialysis.

CEN Case Rep 2021 Jul 28. Epub 2021 Jul 28.

Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-dori, Chuo-ku, Niigata, 951-8120, Japan.

Glucocorticoids are widely used for treating underlying renal diseases and following renal transplantation and are often tapered or discontinued upon reaching end-stage renal failure. Although glucocorticoid withdrawal is the predominant cause of secondary adrenal insufficiency, no consensus has been established regarding its prevalence, clinical manifestations, or therapeutic regimen, for prevention of this pathological condition. We describe a 29-year-old woman admitted to our hospital because of 1-week history of fever, diarrhea, and general fatigue. Read More

View Article and Full-Text PDF

Efficacy and safety among second-generation and other basal insulins in adult patients with type 1 diabetes: a systematic review and network meta-analysis.

Naunyn Schmiedebergs Arch Pharmacol 2021 Jul 28. Epub 2021 Jul 28.

Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka, 565-0871, Japan.

We aimed to assess the comparative efficacy and safety of second-generation basal insulins (glargine U300 and degludec U100) vs. neutral protamine Hagedorn (NPH) and first-generation basal insulins (glargine U100 and detemir) in type 1 diabetes (T1D) adults.PubMed, the Cochrane Library, ClinicalTrials. Read More

View Article and Full-Text PDF

Hyperinsulinemic Hypoglycemia in Neonates Due to Perinatal Stress: A Case Series.

Indian Pediatr 2021 Jul;58(7):688

Department of Neonatology, BLK Superspeciality Hospital, Pusa Road, New Delhi.

View Article and Full-Text PDF

Heterogeneity amongst GLP-1 RA cardiovascular outcome trials results: can definition of established cardiovascular disease be the missing link?

Diabetol Metab Syndr 2021 Jul 27;13(1):81. Epub 2021 Jul 27.

Department of Endocrinology, Diabetes and Metabolism, Centro Hospitalar E Universitário S. João, Porto, Portugal.

Atherosclerotic cardiovascular diseases are the leading cause of adverse outcomes in patients with type 2 diabetes, and all new anti-diabetic agents are mandated to undergo cardiovascular outcome trials (CVOTs). Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are incretin mimetics that reduce blood glucose levels with a low associated risk of hypoglycaemia. CVOTs with different GLP-1 RAs yielded different results in terms of major cardiovascular composite outcome (MACE), with some trials showing superiority in the treatment arm, whereas other simply displayed non-inferiority. Read More

View Article and Full-Text PDF

Angiotensin-Converting Enzyme Inhibitors Used Concomitantly with Insulin Secretagogues and the Risk of Serious Hypoglycemia.

Clin Pharmacol Ther 2021 Jul 27. Epub 2021 Jul 27.

Center for Pharmacoepidemiology Research and Training, Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Serious hypoglycemia is a major adverse event associated with insulin secretagogues. Previous studies have suggested a potential relationship between angiotensin-converting enzyme inhibitors (ACEIs) used with sulfonylureas and serious hypoglycemia, and widely used drug compendia warn of this potential drug-drug interaction. We investigated the association between serious hypoglycemia and concomitant use of ACEIs in patients receiving insulin secretagogues, using the self-controlled case series design and Medicaid claims data from 5 US states linked to Medicare claims from 1999-2011. Read More

View Article and Full-Text PDF

Management of type 2 diabetes in chronic kidney disease.

BMJ Open Diabetes Res Care 2021 Jul;9(1)

VA Health Services Research and Development Center for Innovations in Quality, Effectiveness and Safety, Houston, Texas, USA

The management of patients with type 2 diabetes and chronic kidney disease (CKD) encompasses lifestyle modifications, glycemic control with individualized HbA1c targets, and cardiovascular disease risk reduction. Metformin and sodium-glucose cotransporter-2 inhibitors are first-line agents. Glucagon-like peptide-1 receptor agonists are second-line agents. Read More

View Article and Full-Text PDF

Unusual case of recurrent hypoglycaemia in multiple bee sting envenomation.

BMJ Case Rep 2021 Jul 26;14(7). Epub 2021 Jul 26.

Emergency Medicine, All India Institute of Medical Sciences-Rishikesh, Dehradun, Uttarakhand, India

A bee sting can result in allergic and toxin-mediated local manifestations like pain, swelling, redness and itching to serious systemic effects like acute kidney injury (AKI), pancreatitis, Kounis syndrome and stroke. Melittin and phospholipase A2, which make up 62% of honeybee venom, have vasoactive, haemolytic properties causing severe AKI. Its role in lowering blood glucose in diabetics is an interesting research topic. Read More

View Article and Full-Text PDF

Technical aspects of pediatric robotic pancreatic enucleation based on a case of an insulinoma.

Int J Med Robot 2021 Jul 23:e2317. Epub 2021 Jul 23.

Department of Pediatric Surgery, Protestant Hospital of Bethel Foundation, University Hospital OWL, Campus Bielefeld Bethel, University of Bielefeld, Bielefeld, Germany.

Background: Insulinomas are rare insulin-producing pancreatic neuroendocrine tumors leading to severe episodes of hypoglycemia. Surgery is the predominant curative therapy.

Methods: We report here the first pediatric case of an insulinoma of the pancreatic body resected completely robotically under ultrasound guidance in a 10-year-old male with multiple endocrine neoplasia type 1. Read More

View Article and Full-Text PDF

Postbariatric hypoglycemia: symptom patterns and associated risk factors in the Longitudinal Assessment of Bariatric Surgery study.

Surg Obes Relat Dis 2021 May 19. Epub 2021 May 19.

Research Division, Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts.

Background: Postbariatric hypoglycemia (PBH) can be a devastating complication for which current therapies are often incompletely effective. More information is needed regarding frequency, incidence, and risk factors for PBH.

Objectives: To examine hypoglycemia symptoms following Roux-en-Y gastric bypass (RYGB) and laparoscopic adjustable gastric banding (LAGB) and baseline and in-study risk factors. Read More

View Article and Full-Text PDF

Simulation Platform Development for Diabetes and Technology Self-Management.

J Diabetes Sci Technol 2021 Jul 22:19322968211029303. Epub 2021 Jul 22.

The Ohio State University Medical Center, Columbus, OH, USA.

Background: Specialized education is critical for optimal insulin pump use but is not widely utilized or accessible. We aimed to (1) test the usability and acceptability of A1Control, a simulation platform supporting insulin pump education, and (2) determine predictors of performance.

Method: Rural adult insulin pump users with type 1 diabetes (T1D) participated in a mixed methods usability study in 2 separate rounds. Read More

View Article and Full-Text PDF

Influence of Insulin Application Time and High-Intensity Intermittent Exercise on Hypoglycemic Risk in Adolescents With Type 1 Diabetes.

Pediatr Exerc Sci 2021 Jul 26:1-7. Epub 2021 Jul 26.

Federal University of Paraná.

Purpose: The study analyzed the influence of exercise on hypoglycemia episodes postexercise and in the subsequent 24 hours in children and adolescents with type 1 diabetes.

Methods: Thirty young people performed the same protocol of physical exercises for 1 hour (Ex1h) and 2 hours (Ex2h) after the administration of insulin. They performed 30 minutes of exercise on a cycle ergometer with a load of 60% of maximal oxygen uptake, interspersed with maximum intensity sprints lasting 10 seconds every 5 minutes. Read More

View Article and Full-Text PDF

Efficacy and safety of 28-day treatment with oral insulin (ORMD-0801) in patients with type 2 diabetes mellitus - A randomized placebo-controlled trial.

Diabetes Obes Metab 2021 Jul 26. Epub 2021 Jul 26.

Oramed Pharmaceuticals, Jerusalem, Israel.

Aims: To assess the safety and efficacy of oral insulin (ORMD-0801) in type 2 diabetes (T2DM) patients.

Materials And Methods: After a 2-week washout of other medications, adult metformin-treated patients with T2DM, were randomized to receive placebo or 16 mg or 24 mg ORMD-0801, once daily, at bedtime, for 28 days. The mean change from baseline weighted mean night-time glucose levels was determined from two nights of continuous glucose monitoring (CGM) recordings during the placebo run-in and last week of treatment. Read More

View Article and Full-Text PDF

CBG Montevideo: A Clinically Novel Mutation Leading to Haploinsufficiency of Corticosteroid-binding Globulin.

J Endocr Soc 2021 Sep 22;5(9):bvab115. Epub 2021 Jun 22.

Endocrine and Metabolic Unit, Royal Adelaide Hospital, Adelaide, SA 5000, Australia.

Corticosteroid-binding globulin (CBG) is the main transport protein for cortisol, binding up to 90% in a 1:1 ratio. CBG provides transport of cortisol within the circulation and targeted cortisol tissue delivery. Here, we describe the clinically novel "CBG Montevideo" a pathogenic variant that results in a 50% reduction in plasma CBG levels. Read More

View Article and Full-Text PDF
September 2021

Insulinoma With Concomitant Insulin Antibodies.

AACE Clin Case Rep 2021 Jul-Aug;7(4):247-248. Epub 2021 Feb 3.

Department of Endocrinology, Diabetes & Metabolism, Cleveland Clinic Foundation, Cleveland, Ohio.

Objective: The coexistence of insulinoma and insulin antibodies is extremely rare. The aim of this novel case report is to inform physicians of the possibility of an insulinoma with concomitant insulin antibodies.

Methods: In this report, we describe a patient with symptomatic hypoglycemia confirmed with a 72-hour fast, who was subsequently found to have an insulinoma with concomitant elevation in his immunoglobulin G insulin antibody titer. Read More

View Article and Full-Text PDF
February 2021

Pseudohyperglycemia Secondary to High-Dose Intravenous Vitamin C Managed as Diabetic Ketoacidosis: An Endocrinological Catastrophe.

AACE Clin Case Rep 2021 Jul-Aug;7(4):239-242. Epub 2020 Nov 28.

Department of Internal Medicine, Wellstar Atlanta Medical Center, Atlanta, Georgia.

Objective: To create awareness among health care professionals and nurses regarding interference with point-of-care (POC) blood glucose (BG) meter by high-dose intravenous vitamin C and other potential substances. We report a case that probably resulted in the death of a patient from an erroneous interpretation of POC-BG readings due to interference from high-dose vitamin C.

Methods: Retrospective case review. Read More

View Article and Full-Text PDF
November 2020

Driving Safety and Real-Time Glucose Monitoring in Insulin-Dependent Diabetes.

Int J Automot Eng 2019 4;10(1):34-40. Epub 2019 Feb 4.

University of Nebraska Medical Center, College of Medicine, Department of Neurological Sciences 988440 Nebraska Medical Center, Omaha, NE, 68198.

Our goal is to address the need for driver-state detection using wearable and in-vehicle sensor measurements of driver physiology and health. To address this goal, we deployed in-vehicle systems, wearable sensors, and procedures capable of quantifying real-world driving behavior and performance in at-risk drivers with insulin-dependent type 1 diabetes mellitus (DM). We applied these methodologies over 4 weeks of continuous observation to quantify differences in real-world driver behavior profiles associated with physiologic changes in drivers with DM (N=19) and without DM (N=14). Read More

View Article and Full-Text PDF
February 2019

Recurrent hypoglycemia and a slowly rising hemidiaphragm: A case report.

Clin Case Rep 2021 Jul 21;9(7):e04519. Epub 2021 Jul 21.

Specialist in Diabetes and Endocrinology Royal Devon and Exeter Hospital Exeter UK.

Non-islet cell tumor hypoglycemia should be considered in unexplained recurrent non-insulin-dependent hypoglycemia. Where surgery is not possible steroids may be effective, even at low dose, at managing hypoglycaemia. Read More

View Article and Full-Text PDF

Safety of Semaglutide.

Front Endocrinol (Lausanne) 2021 7;12:645563. Epub 2021 Jul 7.

Diabetes Center, Department of Internal Medicine, Amsterdam University Medical Center, Amsterdam, Netherlands.

The glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide is the most recently approved agent of this drug class, and the only GLP-1RA currently available as both subcutaneous and oral formulation. While GLP-1RAs effectively improve glycemic control and cause weight loss, potential safety concerns have arisen over the years. For semaglutide, such concerns have been addressed in the extensive phase 3 registration trials including cardiovascular outcome trials for both subcutaneous (SUSTAIN: Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes) and oral (PIONEER: Peptide InnOvatioN for the Early diabEtes tReatment) semaglutide and are being studied in further trials and registries, including real world data studies. Read More

View Article and Full-Text PDF

Effect of Dosage Reduction of Hypoglycemic Multidrug Regimens on the Incidences of Acute Glycemic Complications in People With Type 2 Diabetes Who Fast During Ramaḍān: A Randomized Controlled Trial.

Front Endocrinol (Lausanne) 2021 7;12:613826. Epub 2021 Jul 7.

Department of Internal Medicine, The University of Jordan School of Medicine, Amman, Jordan.

Objective: We aimed to investigate the effect of dosage reduction of four hypoglycemic multidrug regimens on the incidences of acute glycemic complications in people with type 2 diabetes who fast during Ramaḍān.

Methods: We conducted an open-label, parallel-group, randomized controlled trial at a tertiary care center in Amman, Jordan. We recruited adults with type 2 diabetes who expressed an intention to fast during Ramaḍān and were adherent to one of four regimens-namely: metformin and glimepiride; metformin and vildagliptin; metformin and insulin glargine U100; or, metformin, insulin glargine U100, and human regular insulin. Read More

View Article and Full-Text PDF

Metabolic hallmarks of liver regeneration.

Trends Endocrinol Metab 2021 Jul 22. Epub 2021 Jul 22.

Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, Academic Center for Education, Culture and Research (ACECR), Tehran, Iran; Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, Academic Center for Education, Culture and Research (ACECR), Tehran, Iran. Electronic address:

Despite the crucial role of cell metabolism in biological processes, particularly cell division, metabolic aspects of liver regeneration are not well defined. Better understanding of the metabolic activity governing division of liver cells will provide powerful insights into mechanisms of physiological and pathological liver regeneration. Recent studies have provided evidence that metabolic response to liver failure might be a proximal signal to initiate cell proliferation in liver regeneration. Read More

View Article and Full-Text PDF

Efficacy and Tolerability of Evogliptin in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis with Bayesian Inference Through a Quality-management System.

Clin Ther 2021 Jul 22. Epub 2021 Jul 22.

College of Pharmacy and Research Institute of Life and Pharmaceutical Sciences, Sunchon National University, Suncheon, Republic of Korea.

Purpose: Evogliptin is one of the latest dipeptidyl peptidase-4 (DPP-4) inhibitor, and a number of clinical trials have been performed following its development, including several randomized controlled trials (RCTs) performed to evaluate its efficacy and tolerability. In our study, we performed a systematic review and meta-analysis of its efficacy and tolerability by collecting RCTs and confirmed the results with Bayesian inference. Moreover, an updated quality-management system was integrated into the study process of systematic review. Read More

View Article and Full-Text PDF

50 Years Ago in TheJournalofPediatrics: Neonatal Hypoglycemia: Progress and Predicaments.

J Pediatr 2021 Aug;235:82

Divisions of Pediatric Endocrinology, Stanford University School of Medicine, Stanford, California.

View Article and Full-Text PDF

50 Years Ago in TheJournalofPediatrics: Advances in the Understanding of Congenital Hyperinsulinemic Hypoglycemia.

J Pediatr 2021 Aug;235:62

Department of Pediatrics, The Children's Hospital at Montefiore and the Albert Einstein College of Medicine, Bronx, New York.

View Article and Full-Text PDF

A Real-World, Prospective, Non-interventional Study of Adults with T2D Switching to IDegAsp from Glargine U100 or U300 in Japan.

Diabetes Ther 2021 Jul 25. Epub 2021 Jul 25.

Division of Diabetes, Metabolism and Endocrinology, Department of Medicine, Toho University Graduate School of Medicine, 6-11-1 Omori-Nishi, Ota-ku, Tokyo, 143-8541, Japan.

Introduction: This real-world study investigated glycaemic control and quality of life (QoL) in insulin-experienced Japanese patients with type 2 diabetes (T2D) who switched to insulin degludec/insulin aspart (IDegAsp).

Methods: This was a prospective, non-interventional, open-label, single-arm study. Eligible patients were adults (aged ≥ 20 years) with T2D, previously treated with insulin glargine 100 or 300 units/mL (glargine U100/U300) with or without prandial insulin, who switched to IDegAsp as part of routine practice. Read More

View Article and Full-Text PDF

Sirolimus in infants with congenital hyperinsulinism (CHI) - a single-centre experience.

Eur J Pediatr 2021 Jul 24. Epub 2021 Jul 24.

Department of Pediatrics Endocrinology Rainbow Children's Hospital, 500034, Hyderabad, India.

Congenital hyperinsulinism (CHI) is the most common cause of persistent hypoglycaemia in neonates and infants. Medical treatment includes the use of high concentrations of glucose and combinations of diazoxide, octreotide and glucagon. We report our experience of using sirolimus, a mammalian target of rapamycin (mTOR) inhibitor, in the treatment of CHI in seven newborns who are poorly responding to standard medical therapy. Read More

View Article and Full-Text PDF

Health-related quality of life in patients with type 2 diabetes initiating a second-line glucose-lowering therapy: the DISCOVER study.

Diabetes Res Clin Pract 2021 Jul 21:108974. Epub 2021 Jul 21.

Peking University People's Hospital, Beijing, China.

Aim: To investigate factors associated with health-related quality of life (HRQoL) in patients with type 2 diabetes mellitus (T2D) at initiation of second-line glucose-lowering therapy.

Methods: DISCOVER is a 3-year, prospective observational study of patients with T2D initiating second-line glucose-lowering therapy, conducted in 38 countries. HRQoL at baseline was assessed using the physical and mental component summary (PCS; MCS) scores of the 36-Item Short Form Health Survey version 2 (SF-36v2) in 31 countries (n=8309) and the Hypoglycaemia Fear Survey-II (HFS-II) in 23 countries (n=6516). Read More

View Article and Full-Text PDF

Evolution of Type 2 Diabetes Management from a Glucocentric Approach to Cardio-Renal Risk Reduction: The New Paradigm of Care.

Drugs 2021 Jul 24. Epub 2021 Jul 24.

Cardiology Unit, Department of Medicine K2, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.

For many years, clinical studies could not show that lowering glucose in patients with type 2 diabetes leads to better macrovascular outcomes. In the past few years, new data have shown that treatment with two classes of dugs developed as "glucose-lowering agents," SGLT2 inhibitors and GLP-1 receptor agonists, can reduce macrovascular and renal complications. These studies have prompted debate about the main aim of type 2 diabetes management. Read More

View Article and Full-Text PDF

In silico studies: Physicochemical properties, drug score, toxicity predictions and molecular docking of organosulphur compounds against Diabetes mellitus.

J Mol Recognit 2021 Jul 24:e2925. Epub 2021 Jul 24.

Department of Chemistry, Avinashilingam Institute for Home Science and Higher Education for Women, Coimbatore, India.

Diabetes mellitus (DM) is a significant common metabolic disorder seen all over the world. In 2020, according to the International Diabetes Federation (IDF), out of 463 million people who have diabetes all over the world, 77 million belong to India. As per the statistical prediction, the affected numbers are probably expected to rise to 642 million by 2040. Read More

View Article and Full-Text PDF

Glucose Regulation Beyond HbA in Type 2 Diabetes Treated With Insulin: Real-World Evidence From the DIALECT-2 Cohort.

Diabetes Care 2021 Jul 22. Epub 2021 Jul 22.

Division of Nephrology, Department of Internal Medicine, Ziekenhuisgroep Twente, Almelo and Hengelo, the Netherlands.

Objective: To investigate glucose variations associated with glycated hemoglobin (HbA) in insulin-treated patients with type 2 diabetes.

Research Design And Methods: Patients included in Diabetes and Lifestyle Cohort Twente (DIALECT)-2 ( = 79) were grouped into three HbA categories: low, intermediate, and high (≤53, 54-62, and ≥63 mmol/mol or ≤7, 7.1-7. Read More

View Article and Full-Text PDF

Alternative cause for hypoglycaemia in insulin-treated diabetes mellitus.

BMJ Case Rep 2021 Jul 23;14(7). Epub 2021 Jul 23.

Endocrinology & Diabetes, Luton and Dunstable University Hospital, Bedfordshire Hospitals NHS Foundation Trust, Luton, UK

We present a case of a 73-year-old woman who developed recurrent hypoglycaemia during a prolonged hospital stay following a mechanical fall. She had a complex history of insulin-treated diabetes mellitus, hypothyroidism, diffuse systemic cutaneous sclerosis, Raynaud's disease, previous breast cancer, Barrett's oesophagus and previous partial gastrectomy for a benign mass. Hypoglycaemia persisted despite weaning of insulin. Read More

View Article and Full-Text PDF